These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 22750722)

  • 1. Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases.
    Mei H; Xia T; Feng G; Zhu J; Lin SM; Qiu Y
    Drug Discov Today; 2012 Nov; 17(21-22):1208-16. PubMed ID: 22750722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Practical Guide for Exploring Opportunities of Repurposing Drugs for CNS Diseases in Systems Biology.
    Mei H; Feng G; Zhu J; Lin S; Qiu Y; Wang Y; Xia T
    Methods Mol Biol; 2016; 1303():531-47. PubMed ID: 26235090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinase inhibitors for CNS diseases: an analysis of the recent patent literature.
    Amigoni F; Legnaghi E; Pevarello P
    Pharm Pat Anal; 2012 May; 1(2):177-92. PubMed ID: 24236782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents.
    Cole PE; Schwarz AJ; Schmidt ME
    Clin Pharmacol Ther; 2012 Feb; 91(2):315-20. PubMed ID: 22218072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges in the search for drugs to treat central nervous system disorders.
    Enna SJ; Williams M
    J Pharmacol Exp Ther; 2009 May; 329(2):404-11. PubMed ID: 19182069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress and promise of antisense oligonucleotide therapeutics for central nervous system diseases.
    Bishop KM
    Neuropharmacology; 2017 Jul; 120():56-62. PubMed ID: 27998711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central nervous system drug development, basic, and clinical research: thinking outside the box.
    Klein DF; Glick ID; Shader RI
    J Clin Psychopharmacol; 2011 Oct; 31(5):553-4. PubMed ID: 21869701
    [No Abstract]   [Full Text] [Related]  

  • 8. Society for Neuroscience - 39th Annual Meeting. Part 2 - Novel therapies for neurodegenerative disorders and other CNS diseases.
    Al-Shamahi A; Kirkham K; Hookes L
    IDrugs; 2009 Dec; 12(12):734-7. PubMed ID: 19943211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translational CNS medicines research.
    Palmer AM; Alavijeh MS
    Drug Discov Today; 2012 Oct; 17(19-20):1068-78. PubMed ID: 22580061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of the vasopressin system for the treatment of CNS diseases.
    Ryckmans T
    Curr Opin Drug Discov Devel; 2010 Sep; 13(5):538-47. PubMed ID: 20812145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges.
    Geerts H; Wikswo J; van der Graaf PH; Bai JPF; Gaiteri C; Bennett D; Swalley SE; Schuck E; Kaddurah-Daouk R; Tsaioun K; Pelleymounter M
    CPT Pharmacometrics Syst Pharmacol; 2020 Jan; 9(1):5-20. PubMed ID: 31674729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trials in CNS--SMi's eighth annual conference.
    Kirk R
    IDrugs; 2010 Feb; 13(2):66-9. PubMed ID: 20127552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico repositioning of approved drugs for rare and neglected diseases.
    Ekins S; Williams AJ; Krasowski MD; Freundlich JS
    Drug Discov Today; 2011 Apr; 16(7-8):298-310. PubMed ID: 21376136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An audience with...Luca Santarelli. Interview by Alexandra Flemming.
    Santarelli L
    Nat Rev Drug Discov; 2013 Jan; 12(1):14-5. PubMed ID: 23274461
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular imaging as a de-risking tool: coming into focus?
    Mullard A
    Nat Rev Drug Discov; 2013 Apr; 12(4):251-2. PubMed ID: 23535924
    [No Abstract]   [Full Text] [Related]  

  • 16. European Neuroscience--Seventh Biennial FENS Forum.
    Hannan AJ
    IDrugs; 2010 Sep; 13(9):607-9. PubMed ID: 20799140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of pharmacogenetics in treating central nervous system disorders.
    Patnaik M; Renda MJ; Athanasiou MC; Reed CR
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1504-9. PubMed ID: 18849543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Trials in CNS--SMi's Seventh Annual Conference. 25-26 November 2008, London, UK.
    Sherwood D
    IDrugs; 2009 Feb; 12(2):84-6. PubMed ID: 19204879
    [No Abstract]   [Full Text] [Related]  

  • 19. Phenotypic screening of the Prestwick library for treatment of Parkinson's tremor symptoms using a humanized quantitative systems pharmacology platform.
    Spiros A; Roberts P; Geerts H
    J Parkinsons Dis; 2013; 3(4):569-80. PubMed ID: 24192755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commercial viability of CNS drugs: balancing the risk/reward profile.
    Johnson GS
    Neurobiol Dis; 2014 Jan; 61():21-4. PubMed ID: 24121113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.